TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04469959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Dopa
Description: Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Dopa
Description: Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Step 1 (3 weeks) Carbidopa/levodopa-matched placebo capsules 3 times. Followed by 1 week of taper. Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Step 1 (3 weeks) Carbidopa/levodopa-matched placebo capsules 3 times. Followed by 1 week of taper. Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.
Study: NCT05547607

Intervention type: DIAGNOSTIC_TEST
Intervention: advanced cardiac imaging
Description: In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).

Intervention type: DIAGNOSTIC_TEST
Intervention: advanced cardiac imaging
Description: In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).
Study: NCT05264519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot bath intervention
Description: Students in this group will have their feet soaked in water with a temperature of 38-42 degrees for 20 minutes, half an hour before bedtime.
Study: NCT06649448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efbemalenograstim alfa Injection
Description: This product should be administered subcutaneously 48 hours after the completion of anti-tumor drug administration in each chemotherapy cycle. The recommended dose for adults is 20mg administered subcutaneously once per chemotherapy cycle. Please do not administer this product within 14 days before and 24 hours after the administration of cytotoxic chemotherapy drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efbemalenograstim alfa Injection
Description: This product should be administered subcutaneously 48 hours after the completion of anti-tumor drug administration in each chemotherapy cycle. The recommended dose for adults is 20mg administered subcutaneously once per chemotherapy cycle. Please do not administer this product within 14 days before and 24 hours after the administration of cytotoxic chemotherapy drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efbemalenograstim alfa Injection
Description: This product should be administered subcutaneously 48 hours after the completion of anti-tumor drug administration in each chemotherapy cycle. The recommended dose for adults is 20mg administered subcutaneously once per chemotherapy cycle. Please do not administer this product within 14 days before and 24 hours after the administration of cytotoxic chemotherapy drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin/cisplatin-etoposide
Description: one of the following chemotherapy regimens can be selected: EC, Q3W: Carboplatin AUC = 5\~6 on Day 1; Etoposide 80\~100 mg/m² on Days 1-3. EP, Q3W: Cisplatin 75\~80 mg/m² on Day 1; Etoposide 80\~100 mg/m² on Days 1-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin plus Paclitaxel
Description: For non-small cell lung cancer (squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Carboplatin AUC = 5\~6 on Day 1 + Taxane: Paclitaxel 175-200 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, administered every 3 weeks (Q3W); Cisplatin/Carboplatin 75 mg/m²/AUC = 5\~6 on Day 1 + Gemcitabine 1000 mg/m² on Days 1 and 8, administered every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/pemetrexed or Carboplatin/pemetrexed
Description: For non-small cell lung cancer (non-squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Cisplatin 75 mg/m² on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W).~Carboplatin AUC = 5\~6 on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP regimen
Description: The chemotherapy regimen options include:~TP regimen: Cisplatin 60-80 mg/m² administered via intravenous drip on Day 1 + Taxane: Paclitaxel 175 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, with a treatment cycle of every 3 weeks (Q3W).
Study: NCT04992013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Capsule taken by mouth
Study: NCT06657170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmunary veins reconnection plus hidden slow conduction ablation
Description: Ablation of pulmonary veins reconnections plus the search and ablation of hidden slow conductions sites (HSC) in the left atrium.~HSC sites are defined as EGMs showing highly fragmented or double electrograms in response atrial triple extrastimulus, presenting normal or fractionated electrogram in the sinus rhythm.~After checking for PV's conduction breakthroughs, point-by point ablation targeting HSC-EGMs will be performed.~The end point for HSC+ ablation will be reached with loss of local capture at a given lesion, pacing from the ablation catheter at high output (10V·2ms).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmunary veins (PV) reconnection ablation only
Description: Each vein will be re-assessed by observing PV potentials along the PV ostia and by pacing from the distal bipole of the ablation catheter (10mA at 2ms) within the lesion set with failed capture of the left atrium. In case of PVs reconnection touch-up applications will be performed at the earliest potential site, identified by comparing far-field atrial EGM to near-field local EGM timing, until isolation will be achieved (entrance and exit block).
Study: NCT06620822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 is the worlds first PD-1/IL-2α bispecific antibody fusion protein with an IL-2 arm that has been designed and modified to retain CD25 (IL-2Rɑ) activity to maximize efficacy and high selectivity, and to reduce binding to IL-2Rβγ to reduce systemic toxicity, whereas the PD-1 binding arm allows for blockade of PD-1 and selective delivery of IL-2. Therefore, IBI363 has the ability to simultaneously block the PD-1/PD-L1 pathway and activate the IL-2 pathway, which can more effectively activate tumor-specific T cells. IL-2, as an important cytokine for activating tumor-specific CD8+ T cells, is mechanistically complementary to immune checkpoint inhibitors, and can reverse T-cell depletion, thereby overcoming immune resistance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108+Sintilimab
Description: LM-108 is a humanized monoclonal antibody targeting the human chemokine CC receptor 8 (CCR8) and is able to modulate the tumor microenvironment by specifically removing tumor-infiltrating regulatory T cells (Treg) through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Treg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310+Sintilimab
Description: The principle of CTLA-4 combined with PD-1 therapy is to fully relieve the inhibition of T cells by blocking both CTLA-4 and PD-1 immune checkpoints simultaneously.CTLA-4 inhibitors mainly work in the initial immune response stage by blocking the binding of CTLA-4 to B7 and enhancing the activation and proliferation of the initial T cells; whereas PD-1 inhibitors restore the anti-tumor activity of activated T cells by blocking the binding of PD-1 to its ligand PD-L1/PD-L2 and restoring their anti-tumor activity. and its ligand PD-L1/PD-L2 binding, lifting the functional inhibition of activated T cells and restoring their anti-tumor activity. Combination therapy can fully activate T-cells, improve the immune system\&amp;#39;s ability to recognize and attack tumors, enhance the anti-tumor immune response, and overcome the drug resistance of single therapy, thus improving the therapeutic effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sindilizumab (Sintilimab) is a humanized anti-PD-1 monoclonal antibody that has demonstrated promising anti-tumor activity in several cancer types. It works by blocking the binding of PD-1 to its ligands, PD-L1 and PD-L2, thereby lifting the inhibition of T-cells and restoring the immune system\&#39;s killing function against tumor cells.
Study: NCT06620523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10 1200 mg orally with Glutathione 1000 mg orally
Description: This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group B: Placebo CoQ10 orally and Placebo Glutathione orally
Description: A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.
Study: NCT06622707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio taping
Description: Despite the increasing indications and new application techniques developed all over the world, it is believed that there is a need for evidence regarding the mechanisms of action and effectiveness of kinesio taping. As a result of the literature review, no study was found in which kinesio taping was applied for 72 hours as a non-pharmacological complementary method to reduce postoperative pain after cesarean section and increase postpartum comfort. In this study, it is planned to apply kinesiotaping for 72 hours after cesarean section.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine clinical care
Description: As routine clinical care; Analgesic treatment protocol applied after cesarean section, postnatal care and discharge services are provided

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine clinical care
Description: As routine clinical care; Analgesic treatment protocol applied after cesarean section, postnatal care and discharge services are provided
Study: NCT06622096

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of laboratory exams prescription
Description: Evaluation of laboratory exams prescription
Study: NCT06710457

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESP
Description: Patients will receive an erector spinae plane (ESP) block in addition to standard medical treatment to prevent PONV and postoperative pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No ESP
Description: Patients will receive standard medical treatment to prevent PONV and postoperative pain.
Study: NCT06710860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ScreenTalk AI-based tailored communication intervention
Description: Participants in intervention group will receive the ScreenTalk AI-based intervention consisting of 3 sessions: (1) tailored messages: to provide CRC risk and screening recommendation based on family history and health belief assessment; (2) open dialogue: to communicate with users asking questions related to CRC risk and screening information, underpinned based on professional knowledge database and Large language models; (3) summary session: to provide a picture overview for easy review. The primary outcome (uptake of colonoscopy) will be measured at 3 months post-intervention (T1), 6 months post-intervention (T2), and 12 months post-intervention (T3).
Study: NCT06731426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBM-TAF
Description: CBM-TAF aims to modify TAF by training participants to adopt an interpretation style that is inconsistent with TAF (i.e., having unwanted thoughts is not morally equivalent to acting upon them and/or having unwanted thoughts does not increase the likelihood of feared events happening in real life). To personalize the training, CBM-TAF is designed to address 4 subtypes of OCD (as defined by Dimensional Obsessive-Compulsive Scale; Abramowitz et al., 2010), each of which targets either TAF-moral or TAF-likelihood. Participants will indicate two OCD subtypes that are most relevant to their experiences and only complete scenarios that correspond to their chosen subtypes. For each scenario, participants are instructed to enter a missing letter in a fragmented word and resolve its emotional ambiguity. After then, participants will answer a True/False question related to the given scenario to verify their comprehension and consolidate their acquisition of healthier interpretation style.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBM-SMP
Description: CBM-SMP is a comparable intervention to CBM-TAF (Siwiec et al., 2023), which aims to provide general education about stress and stress management techniques. It is identical to CBM-TAF in terms of its administration, except for the content of scenarios included in training sessions. For each scenario, participants are instructed to enter a missing letter in a fragmented word. After then, participants will answer a True/False question related to the given scenario in order to verify their comprehension.
Study: NCT06730776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical medication
Description: It will be given to all participants in both groups (A\&B). The most commonly prescribed topical medication is lidocaine ointment 5% (Xylocaine jelly 2% or ointment 5%; AstraZeneca Pharmaceuticals LP, Wilmington, DE), applied as required for symptoms and for 30 minutes before sexual activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical medication
Description: It will be given to all participants in both groups (A\&B). The most commonly prescribed topical medication is lidocaine ointment 5% (Xylocaine jelly 2% or ointment 5%; AstraZeneca Pharmaceuticals LP, Wilmington, DE), applied as required for symptoms and for 30 minutes before sexual activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: This procedure will be applied for group B only. Before starting the first treatment session, each patient will be instructed briefly about the nature of the treatment to gain the patient's confidence and cooperation. This procedure will be performed by using TENS device on acupoints as the following: The participating woman will be placed in a relaxed comfortable supine position with her back well supported. The surface of the treated skin and the electrodes will be cleaned with alcohol wipe. The TENS protocol consists of a 30-minute weekly. session for 10 weeks of biphasic pulses with modulation 0/10-50 Hz of frequency and 300/100/3000 microseconds of pulse duration (s). The intensity parameter will be adapted individually according to each woman's perception, and modulated so that it is applied without discomfort, ranging between 10 and 100 mA (pulsing sensation) (Dionisi and Senatori ,2011)
Study: NCT06730009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLOG + Allogeneic NK cell
Description: Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)~Biological:~Allogeneic Magicell-NK contains NK cells suspended in 100 mL of normal saline Ph I dose starts at 10 × 10\^8 cells (Cohort 1) and escalates to 20 × 10\^8 cells (Cohort 2).~Ph II dose will be determined lower than or equal to Ph I MTD/MFD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SLOG chemotherapy
Description: Drug: SLOG chemotherapy S-1, leucovorin, oxaliplatin, and gemcitabine (SLOG)
Study: NCT06730503

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Observe a situation before and after immunotherapy
Study: NCT04717713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid injection
Description: steroid injection at surgical location

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline injection at surgical location
Study: NCT05296252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mind-wandering intervention
Description: Participants in this condition receive a brief introduction to the potential impact of mind-wandering (before learning, proactive), and are redirected to lesson if probe-caught mind-wandering are endorsed (during learning, reactive)
Study: NCT05345769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AM712(ASKG712)
Description: AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
Study: NCT04579445

Intervention type: OTHER
Intervention: Education on tailored Quality Improvement measures
Description: Centers will undergo an education on defined Quality of Care measures, with the aim to implement a standardized pathway which is reproducible, scalable and which will allow increased access. The implementation of these measures will help to reduce resource requirements, intensive care bed occupancy and overall length of hospital stay with uncompromised patient safety.
Study: NCT06215469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amma Portable Scalp Cooling System (PSCS)
Description: The unit is a compact, mobile refrigeration unit which circulates liquid coolant at low pressure through a special cooling cap on the participant's head, administered during non-investigational, cancer treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of Life (QoL) and device usage questionnaires
Study: NCT05296252

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mind-wandering comparison
Description: Participants in this condition receive no introduction, and only redirection, and the redirection is random, not in reaction to mind-wandering
Study: NCT03330067

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cold and dry CO2 pneumoperitoneum
Description: In this arm, patients undergo pneumoperitoneum by the insufflation of cold (19-21°C) and nonhumidified (0%) CO2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm and humidified CO2 pneumoperitoneum
Description: In this arm, patients undergo pneumoperitoneum by the insufflation of warmed (95° F) and humidified (95% relative humidity) CO2, using a Lexion Insuflow device.
Study: NCT04761406

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phaeosol group
Description: In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor.
Study: NCT06531772

Intervention type: DRUG
Intervention: Antitubercular Agents
Description: Full regimen of antitubercular drugs for 6 month period or longer as justified by patient condition

Intervention type: DRUG
Intervention: Antitubercular Agents
Description: Full regimen of antitubercular drugs for 6 month period or longer as justified by patient condition
Study: NCT05334706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
Description: Sterile suspension, 0.5 ml dose, intramuscular administration in a 3 dose-regimen (Day 1, Month 2, Month 6), prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein from 9 HPV types: 6/11/16/18/31/33/45/52/58.~9vHPV is currently indicated in the EU in individuals from 9 years of age for the prevention of diseases caused by vaccine's 9 HPV types: genital warts (HPV6 and 11) and premalignant lesions and cancers affecting the cervix, vulva, vagina and anus (HPV16, 18, 31, 22, 45, 52 and 58). It was authorized for marketing in the EU on June 9th, 2015.
Study: NCT06024135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoKidney
Description: Progressive exposition to NeoKidney device starting with only one NeoKidney therapy on a mid-week day and 5 SDHD sessions with the usual device in week one, followed by 2 NeoKidney therapies and 4 SDHD sessions with the usual device in week 2, and only progressing to a full week on NeoKidney after a safety review.
Study: NCT05012397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAIN-32
Description: 260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
Study: NCT05924048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reducing the Oxygen Concentration From 5% to 2%
Description: Effect of Reducing the Oxygen Concentration From 5% to 2% in arm 1.